Our core expertise lies in exporting finished pharmaceutical dosage forms – tablets, capsules, injections, PFS, vaccines, syrups to our worldwide customers. We are cognizant about timely delivery and best quality products to our client. We also have offices in Dubai and UK to serve our customers more effectively.

We are reliable pharmaceutical wholesaler with strong network of sourcing partner for our global importers of medical tender supplies in government hospitals, healthcare authorities and NGOs. We offer wide range of products from verified suppliers/manufacturers with global standard accreditations for quality.

Anti-Cancer, Anti-HIV and other critical illness medicines which are not available in India – we have access to those unlicensed medicines. Our procurement network spans global suppliers from which we have access of medicine import.

We provide a customized service to fulfil all your clinical trial supply requirements and reduce your logistical burden. In addition, we offer a range of specialist transport options and storage facilities for cold chain products, which form an integral part of a secure and successful clinical trial supply chain.

At Astound Pharma LLP, we are trying to keep Indian healthcare services to be a global standard. We import innovative diagnostic and surgical devices from Europe and USA to meet high standard of patient safety in hospitals. Currently, we are distributing Sterile Vaginal speculums, PTCA catheters, guiding wires in India.

Governments worldwide have created provisions for granting access to named patient programs to drugs prior to approval for patients who have exhausted all alternative treatment options and do not match clinical trial entry criteria. Often grouped under the labels of compassionate use, expanded access, or named patient supply, these named patient program is governed by rules that vary by country defining access criteria, data collection, promotion, and control of drug distribution. Within the United States, pre-approval demand is generally met through treatment IND (investigational new drug) applications (INDs), or single-patient INDs. These mechanisms, which fall under the label of expanded access programs, provide patient access programs to drugs for groups of patients or individuals residing in the US. Outside the US, named patient programs provide controlled, pre-approval access to drugs in response to requests by physicians on behalf of specific, or “named”, patients before those medicines are licensed in the patient’s home country. Through these programs, patients are able to access drugs in late-stage clinical trials or approved in other countries for a genuine, unmet medical need, before those drugs have been licensed in the patient’s home country.